Phase II Study of Alternating Sunitinib and Temsirolimus
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on
agents directed at blocking tumor and vascular growth pathways. Sunitinib blocks the vascular
endothelial growth factor receptor (VEGFr) and temsirolimus is an inhibitor of mammalian
target of rapamycin (mTOR). Both sunitinib and temsirolimus are FDA approved agents for mRCC.
When agents like these are given together, the toxicity increases but they can be given
safely, at full doses, sequentially. We hypothesize that alternating these agents will double
the progression free survival (PFS) of the agents when given sequentially.